Vectura Group plc Notice of Interim Results (2823M)

TIDMVEC

RNS Number : 2823M

Vectura Group plc

12 October 2016

Vectura Group plc

Notice of Interim Results

Chippenham, UK, 12 October 2016: Vectura Group plc (LSE: VEC) ("the Group"), an industry-leading inhaled airways disease focused business, plans to announce its Interim Results for the period ending 30 September 2016 on Wednesday 23 November 2016.

In addition to presenting the Interim Results, James Ward-Lilley, Chief Executive Officer, and Andrew Derodra, Chief Financial Officer, will provide an update on the Group's progress and the Skyepharma integration. The presentation will take place during a briefing for analysts which will be held from 9.30am to 11:00am on the morning of results in the Guildhall Room, 85 Gresham Street, London, EC2R 7HE.

A live webcast of the meeting, with the presentation slides, will be available on Vectura's website: http://www.vectura.com/investors/presentations-webcasts/.

- ENDS -

For more information, please contact:

 
Vectura Group plc                                                          [phone] 
 
Andrew Derodra - Chief Financial Officer 
Fleur Wood, Director - Investor Relations and Corporate Communications 
 
Consilium Strategic Communications                                         [phone] 
 
Mary-Jane Elliott / Sue Stuart /                                            [e-mail] 
Jessica Hodgson / Chris Welsh / 
 Melissa Gardiner 
About Vectura 
 
 Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading 
 inhaled airways disease focused business with proprietary formulation and devices across DPI, 
 pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities 
 and collaborations, we believe we can become a leader in the development of inhalation products, 
 increasing our ability to help patients suffering from respiratory diseases. In June 2016 
 Vectura completed a merger with Skyepharma PLC. 
 
 Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with 
 growing global royalty streams, and a portfolio of drugs in clinical development, a number 
 of which have licence agreements with several global pharmaceutical and biotechnology companies 
 including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, 
 Chiesi, Almirall, Janssen, and Tianjin KingYork. 
 
 For further information, please visit Vectura's website at www.vectura.com 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORAKDDDDBDBBKD

(END) Dow Jones Newswires

October 12, 2016 02:00 ET (06:00 GMT)